Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > September 13, 2022
Daily News
September 13, 2022
- Lenvima-Keytruda for HCC Misses PIII Primary Goal: Eisai/Merck
September 13, 2022
- Otsuka’s Brexpiprazole Yields Positive Japan PIII Results for Major Depression
September 13, 2022
- Pfizer Seeks Japan Nod for BA.4/5-Adapted COVID-19 Vaccine
September 13, 2022
- Japan OKs Omicron COVID-19 Vaccines from Pfizer, Moderna
September 13, 2022
- Santen CEO Taniuchi Bows Out for Personal Reasons, EVP Ito Takes Helm
September 13, 2022
- Cosentyx 300 mg Pen Approved in Japan: Novartis
September 13, 2022
- Daiichi’s ADC DS-7300 Shows 32% Response in PI/II Solid Tumor Trial
September 13, 2022
- Enhertu Shows Clinically Meaningful Activity in HER2 Mutant NSCLC: Daiichi/AZ
September 13, 2022
- Moderna CEO Visits Fukuoka for Potential Collaboration with Japan
September 13, 2022
- Kowa Files Parmodia Extended-Release Version in Japan
September 13, 2022
- MHLW Panel Recognizes 2 More Deaths Linked to COVID Jabs
September 13, 2022
- MHLW to Survey Impact of Price Surge, FX on Drugs with High Need for Stable Supply
September 13, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…